NEW YORK – The Access to Comprehensive Genomic Profiling Coalition said this week that it has added Mayo Clinic Laboratories to its members. Founded last November, the partnership of diagnostic firms and laboratory service providers advocates for broad health insurance coverage in the US of comprehensive genomic profiling for patients with advanced cancer.
Data and analytics firms Aetion, Flatiron Health, IQvia, Syapse, and Tempus joined this week to announce the creation of the Real-World Evidence Alliance to advocate the use of real-world evidence in biomedical regulatory decision-making. The RWE Alliance intends to engage policymakers, biopharmaceutical companies, medical device manufacturers, patient groups, and other industry stakeholders including trade associations to educate them about the benefits of real-world evidence.
Burning Rock Biotech said this week that it has launched PRESCIENT (Pan-Cancer Early-Stage Detection by Liquid Biopsy Technique Project), the first blood-based, pan-cancer early-detection study in China using a multiomics approach. The study, led by physicians Jie He and Jie Wang at China's National Cancer Center, is expected to enroll 11,879 participants across 22 cancer types as well as healthy controls. The National Cancer Center will also work with other leading clinical centers, including Beijing Cancer Hospital, Jilin Cancer Hospital, and Hubei General Hospital.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared in Precision Oncology News.